Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Verhoeven, Veronique ^a   Lopez Hartmann, Maja ^a   Remmen, Roy ^a   Wens, Johan ^a   Apers, Sandra ^b   Van Royen, Paul ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Universiteitsplein 1   (Belgium)

Author keywords

Cardiovascular prevention; Cholesterol; Red yeast rice; Statins

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ERECTILE DYSFUNCTION; ERUCTATION; FEMALE; HUMAN; INSOMNIA; LIVER PAIN; MALE; MUSCLE CRAMP; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYALGIA; PHYSICIAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ASCOMYCOTA; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHYSICIANS; RISK FACTORS;

EID: 84880181705     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-178     Document Type: Article

References (33)

1. Ying Sing S, T'ien Jung K'ai W. Chinese technology in the seventeenth century. Sun E-T and Sun S-C, transl 1966, 291-294. London: Pennsylvania State University Press.
2. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!. Arch Intern Med 2010, 170:1722-1727. 10.1001/archinternmed.2010.382, 20975018.
3. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem 1992, 38:150-160.
4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1407-1408. 10.1136/bmj.326.7404.1407, 1126301, 12829526.
5. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. 3437972, 22607822, Cholesterol Treatment Trialists' (CTT) Collaborators.
6. Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R. Heart Protection Study Collaborative Group Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011, 378:2013-2020. 3242163, 22115874, Heart Protection Study Collaborative Group.
7. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012, 33:1635-1701. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
8. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010, 12:322-30. 10.1007/s11883-010-0120-9, 20628837.
9. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011, 27:635-662. 10.1016/j.cjca.2011.05.007, 21963058.
10. Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann Med 2012, 44:419-432. 10.3109/07853890.2011.582135, 21623698.
11. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412. 10.1016/j.amjcard.2006.12.063, 17493470.
12. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012, 110:526-529. 10.1016/j.amjcard.2012.04.026, 22608359.
13. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy - a systematic review. J Am Coll Cardiol 2007, 49:2231-2237. 10.1016/j.jacc.2007.02.049, 17560286.
14. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Li S. Chinese Coronary Secondary Prevention Study Group Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008, 101:1689-1693. 10.1016/j.amjcard.2008.02.056, 18549841, Chinese Coronary Secondary Prevention Study Group.
15. Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC. Chinese Coronary Secondary Prevention Study Group. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 2009, 49:947-956. 10.1177/0091270009337509, 19602720.
16. Reinhart KM, Woods JA. Strategies to preserve the use of statins in patients with previous muscular adverse effects. Am J Health Syst Pharm 2012, 69:291-300. 10.2146/ajhp100700, 22302254.
17. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010, 95:2015-2022. 10.1210/jc.2009-2689, 20444930.
18. Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010, 105:664-666. 10.1016/j.amjcard.2009.10.045, 20185013.
19. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830-839. W147-9, 10.7326/0003-4819-150-12-200906160-00006, 19528562.
20. Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, Gori L, Firenzuoli F, Mugelli A, Vannacci A. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J ClinPharmacol 2008, 66:572-574.
21. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med 2006, 145:474-475. 10.7326/0003-4819-145-6-200609190-00021, 16983142.
22. Gordon RY, Becker DJ. The role of red yeast rice for the physician. Curr Atheroscler Rep 2011, 13:73-80. 10.1007/s11883-010-0145-0, 21061097.
23. Sirtori CR, Galli C, Anderson JW, Sirtori E, Arnoldi A. Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev 2009, 22:244-261.
24. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, 1:CD004816.
25. Prasad V, Vandross A. Cardiovascular primary prevention: how high should we set the bar?. Arch Intern Med 2012, 172:656-659. 10.1001/archinternmed.2012.812, 22529231.
26. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B. Alberta Kidney Disease Network Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011, 183:E1189-E1202. 3216447, 21989464, Alberta Kidney Disease Network.
27. Stagnitti M. Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005 MEPS Statistical Brief. No. 205, http://meps.ahrq.gov/mepsweb/data_files/publications/st205/stat205.pdf. Accessed September 11, 2012.
28. Roberfroid D, Dubois C, Vrijens F, Camberlin C, Farfan-Portet M. Statines in Belgie: evolutie in het gebruik en invloed van het terugbetalingsbeleid. KCE report, 2010, English version https://kce.fgov.be/nl/publication/report/statines-in-belgie-evolutie-in-het-gebruik-en-invloed-van-het-terugbetalingsbelei accessed 11/9/2012.
29. http://www.riziv.fgov.be/drug/nl/statistics-scientific-information/pharmanet/info-spot/2011-09-22/index.htm, accessed 26/9/2012.
30. Krumholz HM, Hayward RA. Shifting views on lipid lowering therapy. BMJ 2010, 341:c3531. 10.1136/bmj.c3531, 20667950.
31. Lebenthal Y, Horvath A, Dziechciarz P, Szajewska H, Shamir R. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials. Arch Dis Child 2010, 95:673-680. 10.1136/adc.2008.157024, 20515970.
32. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am 2012, 96:13-26. 10.1016/j.mcna.2012.01.009, 22391248.
33. Campbell A. Natural ways to lower your cholesterol. Diabetes Self Manag 2010, 27:40-46.